IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6, which specifically inhibits IGF-II actions, is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant Human IGF-BP6 has a calculated mass of 22.3 kDa and consists of 213 amino acid residues, including the IGF-BP domain and thyroglobulin type-I domain. Recombinant Human IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
(BTI-Tn-5B1-4) Hi-5 Insect cells
Insulin-like Growth Factor-Binding Protein 6, IBP-6
RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG
≥ 95% by SDS-PAGE gel and HPLC analyses.
Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 – 0.4 μg/ml.
Calculated Molecular Weight:
Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug)
250μg is the largest vial size for this product.
Larger sizes supplied as multiple 250μg vials.
Not for human use.